PTC596 is primarily used in cancer research due to its ability to target and degrade BMI1, a protein involved in cancer stem cell maintenance. This makes it a potential therapeutic agent for various solid tumors and hematologic malignancies. It has shown activity in preclinical models against cancers such as liposarcoma, glioblastoma, and colorectal carcinoma by disrupting cancer cell proliferation and promoting apoptosis. PTC596 is being investigated in clinical trials to evaluate its safety and efficacy, often in combination with other anticancer therapies. Its role in reducing cancer stem cells may help prevent tumor recurrence and resistance, offering a strategic approach in oncology treatment development.